Nasdaq · Healthcare
EXAGEN INC. (XGN)
As-reported financials and recent SEC filings for EXAGEN INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$66.6M
Net income
$-20.0M
Net margin
-30.0%
Diluted EPS
$-0.93
ROE
-114.3%
P/E (TTM)
—
Market cap
—
Debt / equity
1.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $66.6M | $55.6M | $52.5M | $45.6M | $48.3M |
| Gross profit | $38.8M | $33.1M | $29.5M | $21.3M | $27.7M |
| Operating income | $-14.1M | $-13.6M | $-22.8M | $-46.1M | $-24.1M |
| Net income | $-20.0M | $-15.1M | $-23.7M | $-47.4M | $-26.9M |
| Diluted EPS | $-0.93 | $-0.83 | $-1.34 | $-2.77 | $-1.68 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →8-K2026-06-09
View on EDGAR →SCHEDULE 13G2026-05-27
View on EDGAR →SCHEDULE 13G/A2026-05-20
View on EDGAR →S-82026-05-12
View on EDGAR →10-Q2026-05-11
View on EDGAR →Largest Healthcare peers
Go deeper on XGN
Search EXAGEN INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.